1-([1,2,4]triazolo[4,3-a]pyridin-7-yl)ethanamine, 97%, 500mg

7-Bromo-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride, 95.0%, 250mg

2-Bromo-5-ethylpyridine, 95.0%, 1g

(S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(3-(trifluoromethyl)phenyl)butanoic acid, 96%, 250mg

2-Chloropyrimidine-5-sulfonyl chloride, 95.0%, 100mg

6-Bromobenzo[d][1,3]dioxole-4-carbaldehyde, 95+%, 5g

2-Oxocyclohexaneglyoxylic acid ethyl ester, 95.0%, 250mg

ethyl 3-hydroxyquinoxaline-2-carboxylate, 95.0%, 1g

Zernike phase contrast set PLPHi 10/20/40/100 IOS bright field and dark field position

3-Bromo-4-chloro-5-nitropyridine, 95.0%, 500g

2-(TRITYL-AMINO)-ETHANOL, 95.0%, 250mg

(R)-1-(3-Nitro-5-(trifluoromethyl)phenyl)ethan-1-amine hydrochloride, 98%, 50mg

Biacetyl dioxime, 98.0%, 25g